Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Last trade$169.95
Day change+$2.37 (+1.41%)
Day range$165.24 – $171.32
Volume3,146,331
Market cap$207.86B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$207.86B
Price / earnings
—
Price / book
15.94×
Price / sales
6.71×
EV / sales
7.35×
EV / EBITDA
70.11×
Profitability
Earnings per share
-$3.11
Return on assets
-7.51%
Return on equity
-29.62%
Dividend yield
1.97%
Liquidity and leverage
Debt / equity
2.01×
Current ratio
1.38×
Quick ratio
1.22×
Cash ratio
0.54×
Cash flow
Price / cash flow
14.36×
Price / free cash flow
15.08×
Free cash flow
$13.78B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GILD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$8.3B
$7.8B
$6.96B
$7.93B
$7.77B
$7.08B
$6.67B
$7.57B
Cost of revenue
$1.57B
$1.58B
$1.45B
$1.62B
$1.57B
$1.5B
$1.54B
$1.58B
Gross profit
$6.73B
$6.22B
$5.52B
$6.3B
$6.2B
$5.58B
$5.13B
$5.99B
Selling, general and administrative
$1.64B
$1.92B
$1.45B
$1.79B
$1.36B
$1.37B
$1.26B
$1.91B
Research and development
$1.63B
$12.95B
$1.37B
$1.58B
$1.52B
$1.55B
$1.38B
$1.64B
Total operating expenses
$3.27B
$16.62B
$2.93B
$4.32B
$2.87B
$3.11B
$2.89B
$3.54B
Operating income
$3.46B
-$10.39B
$2.59B
$1.98B
$3.33B
$2.47B
$2.24B
$2.45B
Interest expense
-$269M
-$247M
-$240M
-$255M
-$256M
-$254M
-$260M
-$249M
Income before taxes
$3.06B
-$10.25B
$2.58B
$2.08B
$3.64B
$2.43B
$1.65B
$2.17B
Income taxes
$634M
$242M
$559M
-$105M
$589M
$468M
$334M
$385M
Net income
$2.43B
-$10.5B
$2.02B
$2.18B
$3.05B
$1.96B
$1.32B
$1.78B
Net income attributable to common shareholders
$2.43B
-$10.5B
$2.02B
$2.18B
$3.05B
$1.96B
$1.32B
$1.78B
EBITDA
$4.2B
-$7.95B
$3.38B
$3.61B
$4.01B
$3.36B
$3.19B
$3.13B
Basic earnings per share
$1.96
-$8.45
$1.63
$1.76
$2.46
$1.57
$1.06
$1.43
Diluted earnings per share
$1.94
-$8.45
$1.61
$1.74
$2.43
$1.56
$1.04
$1.41
Recent news
Company coverage with links to the original publishers.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.
Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.
The VanEck Biotech ETF (BBH) is a passively managed fund tracking the MVIS US Listed Biotech 25 Index with $521.91 million in assets and a low 0.35% expense ratio. The fund has delivered strong year-to-date returns of 31.47% but carries higher risk with a beta of 0.70 and concentrated exposure through its top 10 holdings representing 73.82% of assets. BBH holds a Zacks ETF Rank of 2 (Buy), though investors should consider alternatives like XBI and IBB.
Three healthcare dividend stocks—AbbVie, Gilead Sciences, and Becton, Dickinson—have significantly outperformed the S&P 500 in 2026, with gains of 29%, 37%, and 43% respectively. All three are recommended as continued buys due to strong underlying businesses, solid dividend programs (two are Dividend Kings), and favorable long-term growth prospects driven by key product pipelines and market tailwinds.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.82 per share
Declared
Oct 27, 2026
Ex-dividend
Dec 15, 2026
Pay date
Dec 30, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 15, 2026
$0.82
Sep 29, 2026
recurring
Jun 15, 2026
$0.82
Jun 29, 2026
recurring
Mar 13, 2026
$0.82
Mar 30, 2026
recurring
Dec 15, 2025
$0.79
Dec 30, 2025
recurring
Sep 15, 2025
$0.79
Sep 29, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.